Cord Blood News Volume 8.19 | May 19 2016

Phase II Study of Intensified Chemotherapy and Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Acute Lymphoblastic Leukemia
Scientists determined the efficacy of an intensified, multi-agent approach derived from a Dana-Farber consortium trial in younger adults for patients older than 50 years. [Cancer] Abstract

Comparative Ability of Mesenchymal Stromal Cells from Different Tissues to Limit Neutrophil Recruitment to Inflamed Endothelium
Scientists compared the effects of mesenchymal stromal cells (MSC) isolated from bone marrow, Wharton’s jelly, and trabecular bone on neutrophil recruitment to cytokine-stimulated endothelial cells (EC), using co-culture models with different degrees of proximity between MSC and EC. [PLoS One] Full Article

A Novel, Bedside Technique to Rapidly Identify Umbilical Cord Blood Units with High Total Nucleated Cell Numbers
The authors established a fast and efficient method for determining total nucleated cell counts at the obstetric ward without exposing the umbilical cord blood units to the environment. [Transfusion] Abstract

Impact of Hematogones on the Long-Term Outcomes of Single-Unit Cord Blood Transplantation for Adult Patients
To evaluate the impact of hematogones on long-term outcomes after single-unit cord blood transplantation, investigators retrospectively analyzed 134 adult patients. [Leuk Lymphoma] Abstract

Transplantation of Human Amniotic Mesenchymal Stem Cells Promotes Neurological Recovery in an Intracerebral Hemorrhage Rat Model
Investigators examined the therapeutic potential of human amniotic membrane mesenchymal stem cells in a rat model of intracerebral hemorrhage, and characterized the possible mechanisms of action. [Biochem Biophys Res Commun] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Arkin Holdings and Primera Capital Lead an Investment of $13 Million in BioSight for an Innovative Treatment of Acute Leukemia
BioSight, Ltd announced the closing of an investment of $13 million led by the Mori Arkin’s pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. [BioSight, Ltd (PR Newswire Association LLC.)] Press Release

From our sponsor: Culturing hematopoietic stem and progenitor cells? Download the technical bulletin.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

NEW Technical Sales Representative (STEMCELL Technologies Inc.)

NEW Postdoctoral Research Associate – Myeloid Leukemia (Upstate Medical University)

Postdoctoral Studies – Computational Transcriptomics and Epigenomics in Acute Myeloid Leukemia (Karolinska Institutet)

Postdoctoral Positions – Stem Cell Biology and Regenerative Medicine (University of Southern California)

Postdoctoral Research Associate – TAM-Family Kinases in Leukemogenesis (Emory University)

Postdoctoral Fellow – Hematopoietic Stem Cells (University of Pennsylvania)

Principal Investigator – Stem Cell Biology and Regeneration Medicine (Guangzhou Women and Children’s Medical Center)

Postdoctoral Research Associate – Pediatric Acute Lymphoblastic Leukemia (University of Pittsburgh)

Associate Scientist – Hematopoietic Stem Cell Biology (Editas Medicine)

Research Associate – Hematopoietic Stem Cell Biology (Editas Medicine)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.